Alpha-6-beta-2-containing nicotinic acetylcholine receptor (α6β2* nAChR)

Alpha-6-beta-2-containing nicotinic acetylcholine receptors (α6β2* nAChRs) are a specific subtype of ligand-gated ion channels primarily localized in the catecholaminergic nuclei of the brain. They are found particularly within the dopaminergic neurons of the substantia nigra and ventral tegmental area [UniProt: P43681]. These receptors play a critical role in modulating the release of dopamine, making them key players in the brain's reward system and motor control pathways [PubMed: 21111911]. Due to their restricted expression pattern compared to the more ubiquitous α4β2 subtype, they represent a highly specific therapeutic target for neurological and psychiatric disorders. In Parkinson's disease, α6β2* receptors are among the first to be lost, suggesting a role in the early pathology of the disease [PubMed: 17202195]. Furthermore, their involvement in the reinforcing effects of nicotine makes them a primary focus for developing smoking cessation aids and treatments for nicotine addiction. Experimental ligands like α-conotoxin MII have been instrumental in characterizing these receptors, though clinical drug development remains focused on achieving high selectivity to avoid off-target effects on other nicotinic subtypes.

Other names

CHRNA6-CHRNB2 nicotinic receptorAlpha-6-beta-2-star nicotinic acetylcholine receptorα6β2* nAChRAlpha-6 subunit-containing nicotinic receptor

Drugs targeting these receptors typically act as agonists, partial agonists, or antagonists to modulate the opening of the cation channel, thereby regulating the release of dopamine in the mesolimbic and nigrostriatal pathways [PubMed: 20633232].